What The 2024 NCCN Guidelines Say About... It does if a single state in the U.S. is any indication. In North Carolina, significantly higher rates of prostate cancer recurrence were reported among men ...
Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...
LOS ANGELES (KABC) -- New technology that's allowing doctors to pinpoint prostate cancer long before it becomes a threat is now widely available. A former firefighter mentioned how this new imaging ...
What The 2024 NCCN Guidelines Say About ...
Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...
Join Tom and Mike as they share an important update on Tom's prostate cancer journey. In this video, they discuss Tom's ...
PSMAddition is an international, open-label, prospective, phase 3 randomized controlled trial of 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC.
A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...
News-Medical.Net on MSN
New trial aims to improve both survival and quality of life for men with advanced prostate cancer
The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...
Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback